TCW Group Inc. Trims Position in Illumina, Inc. (ILMN)

TCW Group Inc. decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 293,199 shares of the life sciences company’s stock after selling 5,664 shares during the period. TCW Group Inc. owned 0.20% of Illumina worth $64,061,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its holdings in Illumina by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 266,817 shares of the life sciences company’s stock worth $46,304,000 after purchasing an additional 1,892 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in Illumina by 2.1% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 5,698 shares of the life sciences company’s stock worth $989,000 after purchasing an additional 116 shares during the last quarter. Advisory Services Network LLC raised its holdings in Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the last quarter. Lord Abbett & CO. LLC raised its holdings in Illumina by 32.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 87,926 shares of the life sciences company’s stock worth $15,257,000 after purchasing an additional 21,347 shares during the last quarter. Finally, Shell Asset Management Co. raised its holdings in Illumina by 24.7% during the 3rd quarter. Shell Asset Management Co. now owns 30,814 shares of the life sciences company’s stock worth $5,051,000 after purchasing an additional 6,103 shares during the last quarter. Institutional investors and hedge funds own 91.12% of the company’s stock.

In related news, EVP Marc Stapley sold 2,000 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $216.87, for a total transaction of $433,740.00. Following the completion of the sale, the executive vice president now directly owns 27,952 shares of the company’s stock, valued at approximately $6,061,950.24. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Charles Dadswell sold 1,610 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $221.45, for a total value of $356,534.50. Following the sale, the senior vice president now directly owns 5,581 shares of the company’s stock, valued at $1,235,912.45. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,440 shares of company stock valued at $21,091,904. 0.89% of the stock is owned by company insiders.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $229.20 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.99 and a quick ratio of 3.55. The company has a market capitalization of $33,690.00, a PE ratio of 38.59, a PEG ratio of 3.03 and a beta of 0.92. Illumina, Inc. has a 52 week low of $158.02 and a 52 week high of $248.97.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.22. The company had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a return on equity of 21.71% and a net margin of 26.56%. Illumina’s revenue was up 25.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.85 EPS. sell-side analysts predict that Illumina, Inc. will post 4.59 earnings per share for the current year.

Several analysts have weighed in on the company. Citigroup raised Illumina from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $260.00 to $275.00 in a report on Monday, February 5th. BidaskClub cut Illumina from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Barclays boosted their price objective on Illumina from $200.00 to $215.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 31st. Morgan Stanley boosted their price objective on Illumina from $145.00 to $157.00 and gave the stock an “underweight” rating in a report on Wednesday, January 31st. Finally, Leerink Swann boosted their price objective on Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $241.39.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/02/20/tcw-group-inc-trims-position-in-illumina-inc-ilmn.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply